Upfront immune checkpoint inhibitors and long-term risk of major adverse cardiovascular events: a population-based propensity-matched cohort study
Findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.